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Summary. The effect ofhyaluronidase and a combination 
of hyaluronidase with Adriamycin was investigated on 
several breast cancer models in vitro and in vivo. In vitro 
enzyme treatment (using concentrations up to 80 000 IU/ 
1) of routine (MXT-, MXT -+, and MXT +) and human 
(MCF-7, ZR-75-1 and T-47-D) breast cancer cell lines 
did not inhibit tumour cell proliferation (measured by a 
kinetic crystal violet assay) in either case. Although high- 
dose hyaluronidase (1.2 x 106 IU/kg) was ineffective, 
when administered peritumourally to the MXT M3.2 
mammary carcinoma of the B6D2F 1 mouse, it is remark- 
able that five "megadoses" were excellently tolerated. 
However, the antineoplastic activity of Adriamycin 
against the oestrogen-receptor-positive variant of the 
MXT tumour was significantly enhanced by combination 
with concentrations of hyaluronidase that were inactive 
per se, both in vitro and in vivo. Interestingly, the en- 
hancement of the in vivo antitumour activity was not 
compromised by toxic side-effects. 
Key words: Hyaluronidase - Adriamycin - Breast cancer 
models - Enhancement ofantitumour activity - No toxic 
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Introduction 
Whereas numerous studies have confirmed the diagnostic 
value of elevated serum levels of hyaluronic acid associ- 
ated with malignant mesothelioma (Frebourg et al. 1987; 
Pettersson et al. 1988; Dahl et al. 1989) and Wilms' 
nephroblastoma (Wu et al. 1984; Stern et al. 1991), there 
have been few reports of raised serum levels in other types 
of advanced cancer (Delpech et al. 1985; Dahl and Lau- 
rant 1988). Cooper and Forbes (1988) presented ata on 
the distribution of serum hyaluronic acid in patients with 
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metastatic cancer or large local tumours (myeloma, mela- 
noma, sarcoma, cancer of the pancreas, stomach, colon, 
lung - small cell and non-small cell, prostate, ovary and 
breast). Within each type of cancer individual patients 
showed strongly elevated levels of hyaluronic acid, but 
statistically significant, overall increased levels were only 
present in pancreatic ancer, small-cell lung cancer and 
carcinoma of the prostate. 
Although increased synthesis of glycosaminoglycans 
is not a universal characteristic oftumours, it seems likely 
that hyaluronic acid production plays an important role 
in tumour cell proliferation, differentiation, invasion and 
metastasis (Knudson et al. 1989). In this context, hy- 
aluronan has been implicated in the pathology of ex- 
perimental nd human breast cancer (Angello et al. 1982; 
Kimata et al. 1983; Marotta et al. 1985; Knudson et al. 
1989; Decker et al. 1989; Prehm 1990). 
Therefore, it is conceivable that breast cancer might be 
an indication for the therapeutic application of hyaluron- 
idase, an enzyme cleaving hyaluronic acid. Hyaluroni- 
dase has for some time been used as an additive to chemo- 
therapy in several studies (Baumgartner 1988) including 
a phase I trial (Baumgartner tal. 1988). 
The pharmacology of hyaluronidase and its potential 
role in the treatment of malignant disease has been re- 
viewed recently (Baumgartner 1987; Baumgartner and 
Moritz 1988). Although the clinical trials have shown en- 
couraging but not definite indications of possible aug- 
mentation of the antitumour activity of the chemothera- 
peutics used after preinfusion of hyaluronidase0 to date 
most of the evidence is "pilot" in nature. 
In addition, preclinical data obtained in cell culture 
(Liu et al. 1987; Kohno et al. 1988; Scheithauer et al. 
1988; Lehnert et al. 1989) and experimental rodent tu- 
mour models (Seipelt and Kohlheb 1967; Pawlowski et 
al. 1979; Sargent et al. 1983) are scanty and inconsis- 
tent. 
As a first approach to characterize the potential effi- 
cacy of hyaluronidase in the therapy of breast cancer, we 
systematically assayed the in vitro chemosensitivity of
various murine (MXT-, MXT § MXT -+) and human 
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(MCF-7,  T-47-D, ZR-75-1) breast cancer cell lines 
against increasing concentrat ions of  hyaluronidase.  As 
an extension of  these experiments, the ant i tumour  activ- 
ity o f  hyaluronidase was tested in vivo, using the syngenic 
MXT M3.2 mammary  carc inoma of  the B6D2F1 mouse. 
Fur ther  studies using the same model  clearly demon-  
strated that hyaluronidase combined with Adr iamyc in  
signif icantly enhanced the ant ineoplast ic effect of  the an- 
thracycline, both in vitro and in vivo. 
Materials and methods 
Chemicals. Reagents (A-grade purity) were obtained from Merck 
(Darmstadt, FRG). N-Hexamethylpararosaniline (crystal violet) 
was purchased from Serva (Heidelberg, FRG). All culture media 
were from Sigma (Miinchen, FRG), and fetal calf serum (FCS) was 
from Gibco (Eggenheim, FRG). Millipore-filtered water was used 
throughout. 
Cell lines and routine culture conditions. The routine cell lines used 
in the in vitro studies were established from different variants of the 
MXT mammary carcinoma of the B6D2F1 mouse (Beckenlehner 
1991). The human breast cancer cell lines (MCF-7, T-47-D and ZR- 
75-1) were obtained from the American Type Culture Collection 
(Rockeville, Md., USA). Cell line banking and quality control were 
performed according to the "seed stock concept" reviewed by Hay 
(1988). 
Proliferation kinetics, karyology, and hormone receptor content 
of the human breast cancer cell lines used in our laboratory have 
been described elsewhere (Bernhardt et al. 1992). 
MCF-7 ceils were grown in Eagle's minimum essential medium 
containing L-glutamine, 2.2 g/1 NaHCOz, 110 mg/l sodium pyru- 
vate (Sigma, Miinchen, FRG), and 10% .FCS. T-47-D was culti- 
vated in RPMI-1640 medium containing L-glutamine, 2.0g/1 
NaHCO3 and 10% FCS. The culture medium was supplemented 
with 10 mg/l bovine insulin (Sigma, Miinchen, FRG). The ZR-75-1 
cell line was maintained in RPMI-1640 medium with L-glutamine, 
2.0 g/1 NaHCO3, 10% FCS and 11.6 mg/1 tylosin. 
The hormone-independent MXT- and MXT -+ sublines were 
oestrogen-receptor-negative. Cells were maintained in RPMI-1640 
medium containing an additional 0.6 g/1 L-glutamine (i.e. 0.9 g/l), 
2.0 g/1NaHHCO3 and 10% FCS. 
The hormone-sensitive and oestrogen-receptor-positive MXT + 
variant required 100 ng/1 oestradiol (Sigma, Mfinchen, FRG) sup- 
plementation of the same basic medium formulation. All culture 
media contained 50 mg/l gentamycin (Sebio, Walchsing, FRG). 
The cells were serially passaged following trypsinization using 
trypsin (0.05%)/EDTA (0.02%) (Boehringer, Mannheim, FRG) 
and cultured in a water-saturated atmosphere of 95% air and 5% 
carbon dioxide at 37 ~ C in 75-cm z culture flasks (Costar, Tecno- 
mara, Fernwald, FRG). 
Drugs. Hyaluronidase from bovine testis was kindly provided in 
highly purified, lyophilized form as Neopermease in vials containing 
200000 IU (specific activity approx. 50000 IU/mg protein) with 
carrier gelatin (25 rag) by Sanabo Gesellschaff m.b.H, (Vienna, 
Austria). The enzyme was dissolved in an appropriate volume of 
deionized water immediately before use. 
Adriamycin (doxorubicin hydrochloride) was purchased from 
Sigma (Mfinchen, FRG). For the in vitro chemosensitivity assay the 
drug was dissolved in 70% (v/v) ethanol; for in vivo testing a solu- 
tion in 0.9% NaC1 was used. 
Chemosensitivity assay. A standardized kinetic microassay based on 
crystal violet staining was used. The technical details of the pro- 
cedure and the method of evaluating drug action have been discus- 
sed recently (Bernhardt et al. 1992). In brief: cells were seeded 
(100 lal/well) in 96-well flat-bottomed microtitration plates (Costar, 
Tecnomara, Fernwald, FRG) at an appropriate density of about 15 
cells/microscopic f eld (magnification 320 x ). After 4248 h (ZR- 
75-1:72 h) the culture medium was removed by suction and replaced 
by medium (200 Ixl/well) containing drug or pure vehicle (gelatin 
carrier dissolved in water; Adriamycin in 70% ethanol). Drugs were 
added as a 1000-fold concentrated stock solution. On every plate 
two rows (n = 16) served as controls and two rows (n = 16) were used 
per drug concentration. After various times of incubation the cells 
were fixed with glutaraldehyde and stored in the refrigerator. At the 
end of the experiment all plates were stained with crystal violet si- 
multaneously. Absorbance was measured at 578 nm using a Biotek 
309 Autoreader (Tecnomara, Fernwald, FRG). Processing pro- 
cedure, data analysis and evaluation were performed as described 
(Reile et al. 1990; Bernhardt et al. 1992). Results are presented as 
plots of absorbance orcorrected T/C values versus time of incuba- 
tion according to T/C .... (%) = 100 x (T -  Co)/(C- Co), where T is 
the absorbance ofthe treated cells, C the absorbance ofthe controls, 
and Co the absorbance ofthe cells at the time when drug was added 
(t=0). 
In vivo testing on the MXT M3.2 mammary carcinoma. Animals were 
housed in Macrolon cages (size III, Ehret, Memmingen, FRG) at an 
ambient emperature of 21 ~ C with a 12-h light/dark cycle. Mice 
were fed with laboratory animal chow (H-1003, Alma, Kempten, 
FRG) and water was provided ad libitum. The ovary-dependent 
MXT M3.2 tumour was propagated by s.c. implantation of about 
2-mm 3 turnout pieces into the right thoracal mammary fat pad of 
intact 8-week-old female B6D2F1 mice (Charles River Wiga, 
Sulzfeld, FRG). The detailed testing procedure and the characteris- 
tics of this tumour model have been described elsewhere (SpruB et 
al. 1991, 1992). Briefly, tumours were implanted subcutaneously 
into the right flank of intact females on day 0, and the animals were 
randomly assigned to groups of ten. 
In the monotherapy experiment treatment was started on day 5 
by injecting 1.2 x 10 6 IU/kg hyaluronidase and vehicle (gelatin car- 
rier) s.c. into the right flank, near to the site of transplantation. 
In the combination therapy experiment hyaluronidase 
(1.2x 106 IU/kg, weekly) was administered peritumourally, 4h 
prior to the i.p. injection of Adriamycin (0.2 mg/kg, three times a 
week). For positive control, one group was ovariectomised 1 day 
after tumour transplantation (day 1). 
Tumour diameters were measured with a caliper. Tumour areas 
were calculated as the product of two perpendicular diameters, one 
measured across the greatest width of the tumour. 
Statistics. Significance l vels of the in vitro data were calculated ac- 
cording to the tn~-test (Sokal and Rohlf 1987 a). The significance 
levels of the median tumour areas after combination therapy (in 
vivo experiment) were determined according to the Mann-Whitney 
U-test (Sokal and Rohlf 1987 b). 
Results 
Effect o f  hyaluronidase on the cell proliferation 
of  breast cancer cells in vitro 
Increasing concentrat ions of  hyaluronidase were tested 
on various mur ine and human breast  cancer cell lines. 
Monotherapy  with 2500, 5000, and 10 000 IU/1 hyaluron-  
idase had no effect on the growth kinetics of  the mur ine 
MXT +- mammary  carcinoma. In accordance with this 
observat ion,  10000 IU/1 enzyme did not  affect cell pro-  
l i feration of  the MXT-  variant.  Increasing doses of  hyal-  
uronidase (10 000, 20 000, 30 000, 40 000, and 50 000 IU/1) 
were not  inhibi tory to the oestrogen-receptor-posit ive 
MXT + subline. Fur ther  dosage escalat ion up to 
80 000 IU/1 was ineffective against he human hormone-  
sensitive MCF-7 ,  ZR-75-1, and T-47-D cell lines. 
High-dose hyaluronidase treatment of the MXT M3.2 
mammary carcinoma of the B6D2F1 mouse 
Tumour-bearing animals were treated with 1.2 x 106 IU/ 
kg hyaluronidase beginning on day 5 after tumour trans- 
plantation. The enzyme was injected s.c. near to the site 
of turnout implantation. Figure 1 shows that administra- 
tion of five single doses (on days 5, 12, 19, 26, and 33) did 
not inhibit tumour growth, whereas typical suppression 
of turnout proliferation by ovariectomy was observed in 
this highly reproducible, ovary-dependent breast cancer 
model. There was no difference in tumour growth when 
gelatin carrier was used instead of the usual NaC1 control 
(Sprul3 et al. 1991). The five "megadoses" of hyaluroni- 
dase were very well tolerated, as indicated by the weight 
gain of the animals during the course of the experiment 
(Fig. 1, inset). At the end of the experiment, no signs of 
toxic side-effects caused by hyaluronidase treatment 
could be detected by routine dissection of the animals. 
Combination therapy with high-dose hyaluronidase 
and Adriamycin 
In vitro testing on MXT + breast cancer cells. The effects 
of Adriamycin monotherapy (50 nM) and combination 
therapy (50 nM Adriamycin with 50 000 IU/1 hyaluroni- 
dase) on cell proliferation using the kinetic crystal violet 
chemosensitivity assay were compared. The results of this 
experiment are summarized in Fig. 2. A slight, but signif- 
icant (P=0.03) increase in the antitumour activity of 
Adriamycin by the addition of a concentration of hyal- 
uronidase inactive per se was observed. 
In vivo enhancement ofAdriamycin activity 
by combination with high-dose hyaluronidase 
As an extension of the in vitro combination therapy ex- 
periments, the corresponding ovary-dependent MXT 
M3.2 mammary tumour model of the B6D2F1 mouse 
was used. Drug treatment s arted on day 19 after tumour 
transplantation, whereas the positive control group was 
ovariectomized on day 1. 
Hyaluronidase (1.2 x 106 IU/kg) was injected peritu- 
mourally 4 h prior to the i.p. injection of nontoxic doses 
of Adriamycin (0.2 mg/kg) on days 19, 26, 33, and 40. 
From day 19, Adriamycin was administered three times 
a week. Tumour growth was only slightly delayed by 
Adriamycin monotherapy, whereas ovariectomy was 
highly effective (Fig. 3). Interestingly, there was a dra- 
matic augmentation of Adriamycin activity by hyaluro- 
nidase pretreatment (P<0.05) (Fig. 3), despite the rela- 
tively late beginning of treatment. As demonstrated 
above (cf. Fig. 1), monotherapy with hyaluronidase was 
ineffective at the same concentration. Remarkably, the 
toxicity of Adriamycin was not enhanced by hyaluroni- 
dase pretreatment (cf. Fig. 3, inset). 
Discussion 
Large amounts of hyaluronic acid are present in several 
types of tumours, including murine and human breast 
cancer (Angello et al. 1980; Knudson et al. 1984a; Knud- 
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Fig. l. Effect of high-dose hyaluronidase therapy of the MXT M3.2 
mammary carcinoma of the B6D2F1 mouse. Hyaluronidase 
(1.2 x 106 IU/kg) was injected peritumourally ondays 5,12, 319, 26, 
and 33. Inset: change of mean body weight during the course 
of treatment. 0, Control (gelatin carrier); ~, treatment group; 
O, ovariectomy control 
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Fig. 2. Combination therapy of MXT + breast cancer cells with 
byaluronidase and Adriamycin vitro. Growth curve of the gelatin 
carrier control (O). Plot of corrected T/C values versus time: 
[], 50 nM Adriamycin; A, combination of 50 nM Adriamycin 
and 50000 IU/I hyaluronidase. At the end of the experiment the 
observed difference between Adriamycin monotherapy and com- 
bination therapy was significant at the P=0.03 level (tnET-test) 
son et al. 1989; Marotta et al. 1985). Elevated hyaluron- 
ate concentrations are not only an in vivo phenomenon; 
isolated mammary turnout cells in culture have also been 
reported to produce glycosaminoglycan (Chandrase- 
karan and Davidson 1979, Knudson et al. 1989), al- 
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Fig. 3. Combination therapy of the MXT M3.2 mammary carci- 
noma of the B6D2F1 mouse with high-dose hyaluronidase and 
Adriamycin. Hyaluronidase (l.2x 10 e IU/kg) was injected peri- 
tumourally, 4 h prior to the i.p. application of0.2 mg/kg Adriamy- 
cin. Hyaluronidase was administered ondays 19, 26, 33, and 40, 
whereas Adriamycin was administered three times a week, starting 
on day 19. Inset: change of mean body weight during the course of 
treatment, e,Gelatin carrier control; LX, Adriamycin monotherapy; 
n, combination therapy with hyaluronidase and Adriamycin; o, 
ovariectomy control. At the end of the experiment the observed dif- 
ference in median tumour area after Adriamycin monotherapy and 
combination therapy was significant at the P < 0.05 level (U-test) 
though frequently in very small amounts. When added to 
cultured cells, hyaluronate can influence mitosis, cell dif- 
ferentiation and proliferation in a complex way. Hya- 
luronic acid is considered to inhibit differentiation and to 
promote cell proliferation instead (Decker et al. 1989). 
Prehm (1990) discussed the observation that high-molec- 
ular-mass hyaluronate inhibits cell growth, whereas mall 
fragments are stimulatory. In addition, it is known that 
hyaluronidase treatment of living cells stimulates the syn- 
thesis of hyaluronic acid (Philipson et al. 1985; Larnier et 
al. 1989), which might result in a feed back inhibition of 
cell proliferation. Our experiments using three murine 
and three human breast cancer cell lines clearly demon- 
strate that cell proliferation was not inhibited by addition 
of increasing concentrations (from 2500 to 80 000 IU/1) 
of bovine testicular hyaluronidase tothe culture medium. 
From these data (the missing inhibition of cell prolifer- 
ation) there was no evidence for a direct dose-dependent 
effect of hyaluronidase on cell-surface constituents such 
as has been speculated by Scheithauer et al. (1988) who 
had measured [14C] glucose metabolism of gastrointesti- 
nal carcinoma cell lines as a function of treatment with 
hyaluronidase and cytostatics. Since not all tumour cells 
synthesize hyaluronate, and we have not checked the 
hyaluronic acid content of our mammary carcinoma cell 
lines, we can not rule out the possibility that in these cell 
lines there is no glycosaminoglycan expression. 
However, there seemed to be a slight tendency to- 
wards growth stimulation of the MXT § and the T-47-D 
cell line. As mentioned above, this could be explained by 
the release of low-molecular-mass oligosaccharides from 
cell-associated hyaluronic acid after hyaluronidase cleav- 
age. 
Although hyaluronidase itself was ineffective in vitro, 
we decided to investigate he effect of high-dose hyaluron- 
idase therapy on the MXT M3.2 mammary carcinoma 
in vivo, since often there ist a discrepancy between the 
large amount of hyaluronic acid found in solid tumours, 
and the only small amounts of polysaccharide produced 
in cell culture. Coculture experiments of tumour cells 
with fibroblasts indicate that the tumour cells stimulate 
the synthesis of hyaluronic acid by fibroblasts (Knudson 
et al. 1984b) via a membrane-bound (Knudson and 
Toole 1988) or a secreted stimulatory factor (Larnier et 
al. 1989; Decker et al. 1989). Thus, interactions between 
tumour cells and fibroblasts of the host seem to be re- 
sponsible for the high hyaluronate concentration found 
in tumours. Forrester and Wilkinson (1981) reported that 
concentrated solutions of hyaluronan inhibited the mi- 
gration of certain types of leukocytes, particularly neu- 
trophils. Inhibition of leukocyte locomotion in combina- 
tion with the formation of hyaluronidase-labile coats 
("halos") around cancer cells, induced in mixed culture 
with peripheral blood mononuclear cells (Z/inker et al. 
1982; Gately et al. 1984), might confer "immunoprotec- 
tion" on the tumour in vivo. In addition, hyaluronate has 
been demonstrated to be unique among the glycosamino- 
glycans in that it can stimulate or inhibit angiogenesis di- 
rectly, depending on its size. Whereas hyaluronate-rich 
stroma inhibits blood vessel formation, low-molecular- 
mass oligosaccharides, as formed by hyaluronidase hy- 
drolysis, stimulate angiogenesis in chick embryos (West 
and Kumar 1989). 
Unfortunately, there was no evidence for the implica- 
tion of the discussed mechanisms above in the prolifer- 
ation of the MXT M3.2 mammary tumour of the 
B6D2F 1 mouse. As shown in Fig. 1, high-dose peritu- 
moural hyaluronidase treatment failed to inhibit tumour 
growth. However, this experiment proved that hyaluroni- 
dase is excellently tolerated, even when administered at 
"megadoses". Our findings are consistent with the "no- 
effect level" of hyaluronidase in mice being 1.5 x 106 IU/ 
kg for a single i.v. injection (Baumgartner and Moritz 
1988). 
Some clinical observations suggest that hyaluronidase 
preinfusion potentiates the effectiveness of chemother- 
apy (Baumgartner 1987, 1988; Baumgartner and Moritz 
1988). The results of our experiments, comparing the 
antitumour activity of Adriamycin itself with the activity 
of a combination of Adriamycin and hyaluronidase 
against breat cancer in vitro and in vivo, support the 
clinical data. Figure 2 shows that the cytotoxic effect of 
Adriamycin against he MXT + celt line was enhanced in 
the presence of hyaluronidase. The augmentation of 
Adriamycin cytotoxicity is consistent with the data re- 
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ported by Lehnert et al. (1989) who could show, in the 
clonogenic assay, that the activity of  doxorubicin on the 
murine P 388 leukemia cell line was enhanced in the pres- 
ence of  hyaluronidase. 
The enhancement of Adr iamycin activity in combina- 
tion with hyaluronidase was even more impressive in vivo 
(cf. Fig. 3). The most straightforward mechanism to ex- 
plain this quantitative difference is the enzymatic degra- 
dation of  the hyaluronate-enriched intercellular matrix in 
solid tumours. By generating hydrated intercellular 
space, hyaluronidase facilitates diffusion of  Adriamycin. 
As a consequence, tumour growth is inhibited indirectly, 
by the improved availability of  the chemotherapeutic. 
In this study we could demonstrate that hyaluroni- 
dase, when administered at high doses, can principally 
potentiate the activity of  Adriamycin against experimen- 
tal breast cancer, without increasing toxic side-effects. 
Further work must prove whether potentiation of  anti- 
neoplastic activity will still be maintained after the sys- 
temic administration of  lower doses of  hyaluronidase. 
Nevertheless, if the results of  these future studies were to 
be negative, high-dose hyaluronidase, in combinat ion 
with chemotherapeutics, may still lead to an improve- 
ment of  the outcome of  isolated limb perfusion, practiced 
in the therapy of  malignant melanoma. 
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